Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH). (May 2019)

• Record Type: Journal Article
• Authors: Escribano-Subias, Pilar; Bendjenana, Hakim; Curtis, Paula S.; Lang, Irene; Noordegraaf, Anton Vonk
• Is Part Of: Pulmonary circulation. Volume 9:Number 2(2019)
• Publication Date: 2019-05
• Subjects: Six-minute walk distance -- 6MWD -- AMBER 1 -- Group 4 pulmonary hypertension; Pulmonary circulation -- Periodicals; Pulmonary circulation; Electronic journals -- Sciences; Periodicals; 616.24005
• DOI: 10.1177/2045894019846433
• Languages: English
• ISSNs: 2045-8932

Abstract

This multicenter, randomized, double-blind, placebo-controlled study assessed ambrisentan or placebo in patients with inoperable chronic thromboembolic pulmonary hypertension. Futility of enrollment led to early termination. Trends of improvement in favor of ambrisentan versus placebo in the primary and some secondary endpoints were observed; adverse event profiles were similar between groups.